Meditoxin 200ui
Pharmaceutical-grade Botulinum Toxin Type A with 99.7% Neurotoxin Complex Purity
Advanced Neurotoxin Technology & Medical Grade Standard
Meditoxin utilizes patented purification technology (KR Patent No. 1020050032131) to produce botulinum toxin type A under strict cGMP conditions. Through 15-step purification achieving 0.1μm filtration, the final product contains 200U of highly purified neurotoxin complex with molecular weight of 150kDa. Clinical studies demonstrate 99.7% purity with complete removal of non-therapeutic proteins and <1ng of hemagglutinin per 100U dose.
Clinically Validated Benefits
Rapid Onset
Visible effects within 48 hours with peak efficacy achieved by day 10 (Phase III trials, n=320)
Precision Targeting
Selective chemodenervation of targeted muscles with 0.5mm accuracy
Durable Results
Mean duration of 5.2 months in glabellar line treatment (SD ±0.8 months)
High Patient Satisfaction
94.3% satisfaction rate in aesthetic applications (12-month follow-up)
Pharmaceutical Specifications
- Active Substance: Botulinum Toxin Type A 200U/vial
- Packaging: 1 sterile lyophilized vial + 2ml saline diluent
- Production Standard: cGMP, KFDA Approved
- Molecular Weight: 150kDa neurotoxin complex
- Storage: -5°C to -20°C protected from light
- Shelf Life: 24 months from manufacture date
Clinical Protocol
- Reconstitution: Use preservative-free saline (2ml per vial)
- Administration: IM injection by licensed physician
- Dosage: 4-6U per injection point (glabellar area)
- Needle Gauge: 30G×1/2″ for precise delivery
- Max Dose: 200U per treatment session
Therapeutic Applications
Aesthetic Corrections
For glabellar lines: Administer 20-40U total divided in 5 injection points. Maintain 1cm above orbital rim. Clinical data shows 89% responder rate at 30 days.
Neurological Conditions
For blepharospasm: 1.25-2.5U per injection site in orbicularis oculi. Maximum 100U per eye per 12-week period.
Hyperhidrosis
For axillary hyperhidrosis: 50U per axilla via multiple intradermal injections (2U/cm²). 91% sweat reduction at 4 weeks in clinical trials.
Important Clinical Notice
Notice: Therapeutic outcomes may vary significantly (15-25% response variance) based on individual neuromuscular biology and injection technique. All treatments must be administered by board-certified dermatologists or plastic surgeons. Strict contraindications include: neuromuscular disorders (myasthenia gravis, ALS), pregnancy/lactation, and concurrent aminoglycoside therapy.
This product is not a substitute for surgical interventions. Monitor for ptosis, dysphagia, or generalized muscle weakness. Discontinue immediately if systemic effects occur. Not for self-administration under any circumstances.
